{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:42:53Z","timestamp":1781023373275,"version":"3.54.1"},"reference-count":54,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023453","name":"Norgine Ltd.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100023453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin\u2014a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption\u2014has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Prospectively registered in the\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05456932\">NCT05456932<\/jats:ext-link>\n                      ) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-077511","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T01:11:24Z","timestamp":1706663484000},"page":"e077511","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05456932","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05456932","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05456932","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-9007","authenticated-orcid":false,"given":"Roberta","family":"Loveikyte","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn","family":"Duijvestein","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatan","family":"Mujagic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier L","family":"Goetgebuer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E","family":"van der Meulen-de Jong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2025121602063095000_14.1.e077511.1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ecco-jcc\/jjx055","article-title":"A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence?","volume":"11","author":"van den Heuvel","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025121602063095000_14.1.e077511.2","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjac190.0025","article-title":"OP25 prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data","volume":"17","author":"Van Linschoten","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025121602063095000_14.1.e077511.3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11226843","article-title":"Anemia and iron deficiency in outpatients with inflammatory bowel disease: ubiquitous yet suboptimally managed","volume":"11","author":"Loveikyte","year":"2022","journal-title":"J Clin Med"},{"key":"2025121602063095000_14.1.e077511.4","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1016\/j.amjmed.2003.12.011","article-title":"Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature","volume":"116 Suppl 7A","author":"Wilson","year":"2004","journal-title":"Am J Med"},{"key":"2025121602063095000_14.1.e077511.5","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1007\/s10620-022-07474-z","article-title":"Iron deficiency in patients with inflammatory bowel diseases: a prospective multicenter cross-sectional study","volume":"67","author":"Peyrin-Biroulet","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2025121602063095000_14.1.e077511.6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ibd\/izac054","article-title":"Prevalence, pathogenesis and management of anemia in inflammatory bowel disease: an IG-IBD multicenter, prospective, and observational study","volume":"29","author":"Bergamaschi","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035758"},{"key":"2025121602063095000_14.1.e077511.8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/anae.15432","article-title":"The misogyny of iron deficiency","volume":"76 Suppl 4","author":"Dugan","year":"2021","journal-title":"Anaesthesia"},{"key":"2025121602063095000_14.1.e077511.9","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s10620-020-06590-y","article-title":"Anemia severity associated with increased healthcare utilization and costs in inflammatory bowel disease","volume":"66","author":"Blaney","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2025121602063095000_14.1.e077511.10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.MIB.0000442728.74340.fd","article-title":"Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis","volume":"20","author":"Filmann","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1055\/a-1283-6832","article-title":"Iron deficiency, depression, and fatigue in inflammatory bowel diseases","volume":"58","author":"K\u00f6nig","year":"2020","journal-title":"Z Gastroenterol"},{"key":"2025121602063095000_14.1.e077511.12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009"},{"key":"2025121602063095000_14.1.e077511.13","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/MIB.0000000000000386","article-title":"Iron replacement in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"21","author":"Abhyankar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000963","article-title":"Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review","volume":"94","author":"Nielsen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2025121602063095000_14.1.e077511.15","article-title":"Interventions for treating iron deficiency anaemia in inflammatory bowel disease","volume":"1","author":"Gordon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121602063095000_14.1.e077511.16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpeds.2022.12.016","article-title":"Ferric carboxymaltose versus ferrous fumarate in anemic children with inflammatory bowel disease: the POPEYE randomized controlled clinical trial","volume":"256","author":"Bevers","year":"2023","journal-title":"J Pediatr"},{"key":"2025121602063095000_14.1.e077511.17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051536","article-title":"Oral iron for IBD patients: lessons learned at time of COVID-19 pandemic","volume":"9","author":"D\u2019Amico","year":"2020","journal-title":"J Clin Med"},{"key":"2025121602063095000_14.1.e077511.18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002308","article-title":"Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Bonovas","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025121602063095000_14.1.e077511.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117383","article-title":"Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis","volume":"10","author":"Tolkien","year":"2015","journal-title":"PLoS One"},{"key":"2025121602063095000_14.1.e077511.20","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040097","article-title":"Sucrosomial\u00ae iron: a new generation iron for improving oral supplementation","volume":"11","author":"G\u00f3mez-Ram\u00edrez","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025121602063095000_14.1.e077511.21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ibd\/izab073","article-title":"Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial","volume":"28","author":"Howaldt","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115546","article-title":"New era in the treatment of iron deficiency anaemia using trimaltol iron and other lipophilic iron chelator complexes: historical perspectives of discovery and future applications","volume":"22","author":"Kontoghiorghes","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025121602063095000_14.1.e077511.23","doi-asserted-by":"crossref","DOI":"10.3390\/ph16060847","article-title":"Sucrosomial\u00ae iron: an updated review of its clinical efficacy for the treatment of iron deficiency","volume":"16","author":"G\u00f3mez-Ram\u00edrez","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025121602063095000_14.1.e077511.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194448","article-title":"Iron replacement therapy with oral ferric maltol: review of the evidence and expert opinion","volume":"10","author":"Schmidt","year":"2021","journal-title":"J Clin Med"},{"key":"2025121602063095000_14.1.e077511.25","article-title":"Disease activity affects response to enteral iron supplementation; post-hoc analysis of data from the aegis study","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut"},{"key":"2025121602063095000_14.1.e077511.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000759","article-title":"Iron deficiency anaemia: pathophysiology, assessment, practical management","volume":"9","author":"Kumar","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2025121602063095000_14.1.e077511.27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073646","article-title":"Long-term iron deficiency and dietary iron excess exacerbate acute dextran sodium sulphate-induced colitis and are associated with significant dysbiosis","volume":"22","author":"Mahalhal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025121602063095000_14.1.e077511.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202460","article-title":"Oral iron exacerbates colitis and influences the intestinal microbiome","volume":"13","author":"Mahalhal","year":"2018","journal-title":"PLoS One"},{"key":"2025121602063095000_14.1.e077511.29","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072269","article-title":"Oral ferric maltol does not adversely affect the intestinal microbiome of patients or mice, but ferrous sulphate does","volume":"13","author":"Mahalhal","year":"2021","journal-title":"Nutrients"},{"key":"2025121602063095000_14.1.e077511.30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.232"},{"key":"2025121602063095000_14.1.e077511.31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309940"},{"key":"2025121602063095000_14.1.e077511.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41522-019-0097-2","article-title":"Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron","volume":"5","author":"La Carpia","year":"2019","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2025121602063095000_14.1.e077511.33","doi-asserted-by":"crossref","DOI":"10.3390\/nu14091926","article-title":"Iron Supplementation at the Crossroads of Nutrition and Gut Microbiota: The State of the Art","volume":"14","author":"Puga","year":"2022","journal-title":"Nutrients"},{"key":"2025121602063095000_14.1.e077511.34","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173478","article-title":"The dark side of iron: the relationship between iron, inflammation and gut microbiota in selected diseases associated with iron deficiency anaemia-a narrative review","volume":"14","author":"Malesza","year":"2022","journal-title":"Nutrients"},{"key":"2025121602063095000_14.1.e077511.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102950","article-title":"The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: a review on the conundrum","volume":"68","author":"Loveikyte","year":"2023","journal-title":"Redox Biol"},{"key":"2025121602063095000_14.1.e077511.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2014.07.072","article-title":"Serum hepcidin and iron absorption in pediatric inflammatory bowel disease: a prospective, comparative study","volume":"46","author":"Martinelli","year":"2014","journal-title":"Digestive and Liver Disease"},{"key":"2025121602063095000_14.1.e077511.37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/ecco-jcc\/jjz149","article-title":"Inflammation, but not the underlying disease or its location, predicts oral iron absorption capacity in patients with inflammatory bowel disease","volume":"14","author":"Aksan","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025121602063095000_14.1.e077511.38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.vh.2019.01.003","article-title":"Signaling pathways regulating hepcidin","volume":"110","author":"Rishi","year":"2019","journal-title":"Vitam Horm"},{"key":"2025121602063095000_14.1.e077511.39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/bs.vh.2019.01.005","article-title":"Regulators of hepcidin expression","volume":"110","author":"Roth","year":"2019","journal-title":"Vitam Horm"},{"key":"2025121602063095000_14.1.e077511.40","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ibd\/izad010","article-title":"Hepcidin and iron status in patients with inflammatory bowel disease undergoing induction therapy with vedolizumab or infliximab","volume":"29","author":"Loveikyte","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208645"},{"key":"2025121602063095000_14.1.e077511.42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.022426"},{"key":"2025121602063095000_14.1.e077511.43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.048926"},{"key":"2025121602063095000_14.1.e077511.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.04.008"},{"key":"2025121602063095000_14.1.e077511.45","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23354"},{"key":"2025121602063095000_14.1.e077511.46","doi-asserted-by":"crossref","DOI":"10.1186\/s40560-018-0328-2","article-title":"Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study","volume":"6","author":"Litton","year":"2018","journal-title":"J Intensive Care"},{"key":"2025121602063095000_14.1.e077511.47","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/ibd\/izab170","article-title":"IBD in the postpartum period: spotlight on maternal outcomes","volume":"28","author":"Br\u00f6ms","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025121602063095000_14.1.e077511.48","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.cgh.2015.10.035","article-title":"Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies","volume":"14","author":"Van Deen","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121602063095000_14.1.e077511.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.02.016"},{"key":"2025121602063095000_14.1.e077511.50","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"2025121602063095000_14.1.e077511.51","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.3748\/wjg.v24.i36.4186","article-title":"Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease","volume":"24","author":"Bengi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025121602063095000_14.1.e077511.52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.15403\/jgld.2014.1121.lpu","article-title":"Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study","volume":"24","author":"Lupu","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025121602063095000_14.1.e077511.53","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac190.0482","article-title":"P352 Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients","volume":"17","author":"Khan","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025121602063095000_14.1.e077511.54","doi-asserted-by":"crossref","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-077511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:06:41Z","timestamp":1765879601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-077511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjopen-2023-077511"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-077511","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}